WO2011002857A3 - 3-cyanoquinoline tablet formulations and uses thereof - Google Patents

3-cyanoquinoline tablet formulations and uses thereof Download PDF

Info

Publication number
WO2011002857A3
WO2011002857A3 PCT/US2010/040555 US2010040555W WO2011002857A3 WO 2011002857 A3 WO2011002857 A3 WO 2011002857A3 US 2010040555 W US2010040555 W US 2010040555W WO 2011002857 A3 WO2011002857 A3 WO 2011002857A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyanoquinoline
tablet formulations
formulations
tablet
ski
Prior art date
Application number
PCT/US2010/040555
Other languages
French (fr)
Other versions
WO2011002857A2 (en
Inventor
Goldi Kaul
Ramarao Chatlapalli
Arwinder Nagi
Krishnendu Ghosh
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI1015941A priority Critical patent/BRPI1015941A2/en
Priority to SG2011094950A priority patent/SG177309A1/en
Priority to CA2766067A priority patent/CA2766067A1/en
Priority to CN2010800294791A priority patent/CN102470109A/en
Priority to RU2011152105/15A priority patent/RU2011152105A/en
Priority to MX2012000048A priority patent/MX2012000048A/en
Application filed by Wyeth Llc filed Critical Wyeth Llc
Priority to AU2010266342A priority patent/AU2010266342A1/en
Priority to EP10732568A priority patent/EP2448563A2/en
Publication of WO2011002857A2 publication Critical patent/WO2011002857A2/en
Publication of WO2011002857A3 publication Critical patent/WO2011002857A3/en
Priority to IL217298A priority patent/IL217298A0/en
Priority to ZA2012/00366A priority patent/ZA201200366B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides solid compositions comprising a 3-cyanoquinoline, SKI-606, and further comprising croscarmellose sodium.
PCT/US2010/040555 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof WO2011002857A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SG2011094950A SG177309A1 (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof
CA2766067A CA2766067A1 (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof
CN2010800294791A CN102470109A (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof
RU2011152105/15A RU2011152105A (en) 2009-07-02 2010-06-30 COMPOSITIONS OF 3-CYANOCHINOLINE TABLETS AND THEIR APPLICATION
MX2012000048A MX2012000048A (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof.
BRPI1015941A BRPI1015941A2 (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and use thereof.
AU2010266342A AU2010266342A1 (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof
EP10732568A EP2448563A2 (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof
IL217298A IL217298A0 (en) 2009-07-02 2011-12-29 3-cyanoquinoline tablet formulations and uses thereof
ZA2012/00366A ZA201200366B (en) 2009-07-02 2012-01-17 3-cyanoquinoline tablet formulations and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22253709P 2009-07-02 2009-07-02
US61/222,537 2009-07-02

Publications (2)

Publication Number Publication Date
WO2011002857A2 WO2011002857A2 (en) 2011-01-06
WO2011002857A3 true WO2011002857A3 (en) 2011-03-10

Family

ID=42732381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/040555 WO2011002857A2 (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof

Country Status (15)

Country Link
EP (1) EP2448563A2 (en)
JP (1) JP2011012063A (en)
KR (1) KR20120046216A (en)
CN (1) CN102470109A (en)
AR (1) AR077546A1 (en)
AU (1) AU2010266342A1 (en)
BR (1) BRPI1015941A2 (en)
CA (1) CA2766067A1 (en)
IL (1) IL217298A0 (en)
MX (1) MX2012000048A (en)
RU (1) RU2011152105A (en)
SG (1) SG177309A1 (en)
TW (1) TW201113050A (en)
WO (1) WO2011002857A2 (en)
ZA (1) ZA201200366B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (en) 2005-02-03 2011-10-31 Wyeth Llc Method for treating gefitinib resistant cancer
PE20070763A1 (en) 2005-11-04 2007-08-08 Wyeth Corp ANTINEOPLASTIC COMBINATIONS OF AN INHIBITOR OF mTOR, TRASTUZUMAB AND / OR HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (en) 2008-06-17 2012-08-22 惠氏有限责任公司 Antineoplastic combinations containing HKI-272 and vinorelbine
CN102202667A (en) 2008-08-04 2011-09-28 惠氏有限责任公司 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
MX356593B (en) 2009-04-06 2018-06-05 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer.
WO2011056741A2 (en) 2009-11-09 2011-05-12 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
RS59599B2 (en) 2009-11-09 2023-03-31 Wyeth Llc Tablet formulations of neratinib maleate
CN104447541A (en) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 Bosutinib compound
CN105384686B (en) * 2014-09-04 2019-07-26 连云港润众制药有限公司 A kind of bosutinib method for crystallising
US20190060325A1 (en) * 2016-04-08 2019-02-28 Shionogi & Co., Ltd. Stabilized solid dosage form
CN110461720A (en) 2017-03-31 2019-11-15 日精Asb机械株式会社 Resin container

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015767A1 (en) * 2005-07-01 2007-01-18 Tesconi Marc S Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
RU2318518C2 (en) * 2002-02-26 2008-03-10 Астразенека Аб Pharmaceutical composition possessing anti-proliferative effect (variants), method for its preparing and methods for its using
RU2345069C2 (en) 2003-08-19 2009-01-27 Уайт Холдингз Корпорейшн Method of obtaining 4-amino-3-quinolinecarbonitryls
KR20070053205A (en) * 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Medicinal composition
WO2008053295A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid
CN101224185A (en) * 2007-12-11 2008-07-23 山东蓝金生物工程有限公司 Bosutinib sustained release implant for treating solid tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015767A1 (en) * 2005-07-01 2007-01-18 Tesconi Marc S Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same

Also Published As

Publication number Publication date
ZA201200366B (en) 2012-10-31
KR20120046216A (en) 2012-05-09
RU2011152105A (en) 2013-08-10
AR077546A1 (en) 2011-09-07
TW201113050A (en) 2011-04-16
CA2766067A1 (en) 2011-01-06
WO2011002857A2 (en) 2011-01-06
BRPI1015941A2 (en) 2016-04-19
EP2448563A2 (en) 2012-05-09
MX2012000048A (en) 2012-01-27
SG177309A1 (en) 2012-02-28
AU2010266342A1 (en) 2012-01-19
CN102470109A (en) 2012-05-23
IL217298A0 (en) 2012-02-29
JP2011012063A (en) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2011002857A3 (en) 3-cyanoquinoline tablet formulations and uses thereof
IL255097A0 (en) Antimicrobial compounds, pharmaceutical compositions comprising them and uses thereof
IL204844A (en) Quinolone analogs, pharmaceutical compositions comprising the same and uses thereof
IL215799A (en) Quinazolone compounds, pharmaceutical compositions comprising the same and uses thereof
WO2006074398A3 (en) Sustained release pharmaceutical formulations comprising ranolazine
IL195488A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL220009A (en) Indole compounds, compositions comprising the same and uses thereof
IL200206A0 (en) Quinoxaline darivatives, their preparation and pharmaceutical compositions containing them
IL206808A (en) Indolyl-pyridone derivatives, pharmaceutical compositions comprising the same and uses thereof
IL220283A0 (en) 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof
IL206395A (en) N-heterocyclyl-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and pharmaceutical compositions comprising them
IL216113A (en) Substituted indazole and aza-indazole derivatives, pharmaceutical compositions comprising them and uses thereof
IL218995A (en) 2, 3, 5-trisubstituted 1h-pyrrole derivatives and pharmaceutical compositions comprising them
WO2009025876A8 (en) Crystalline forms of erlotinib hcl and formulations thereof
EP2285357B8 (en) Pharmaceutical compositions comprising brivaracetam
IL217729A (en) 3-[(piperazin-1-yl)butyl]-4h-chromen-4-one derivatives, processes for their preparation and pharmaceutical compositions comprising them
EP2241569A4 (en) Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses
ZA201200367B (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
PL2155688T3 (en) Dinitropyrazole derivatives, their preparation, and energetic compositions comprising them.
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
IL219243A (en) 5-hydroxypyrimidine-4-carboxamide derivatives, compositions comprising the same and uses thereof
IL210316A (en) Triazole derivatives, pharmaceutical compositions comprising the same and uses thereof
WO2010115125A3 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
EP2284158A4 (en) Quinoline compounds, pharmaceutical compositions, preparation methods and uses thereof
WO2010046061A3 (en) Cosmetic and/or pharmaceutical formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080029479.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10732568

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010266342

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2766067

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10085/DELNP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/000048

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2010266342

Country of ref document: AU

Date of ref document: 20100630

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010732568

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127002851

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011152105

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1015941

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1015941

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111230